首页
热心肠日报
文献库
产业库
榜单
关于日报
《肠·道》演讲
往期精彩
《肠·道》2024
《肠·道》2023
《肠·道》2022
《肠·道》2021
《肠·道》2020
《肠·道》2019
《肠·道》2018
《肠·道》2017
关于《肠·道》
肠道大会
热心肠大会
热心肠智库
智库专家
专家动态
智库新闻
关于智库
奖学金
年度人物奖
更多
HOPE
会议信息
科学与艺术
学术专刊
R·AI
周刊
热心肠先生
研究院动态
关于我们
搜索
登录
关闭
手机邮箱登录
扫码登录
微信扫描二维码快捷登录
验证成功,将在
3
秒钟后跳转
已超时,请
重试
关闭
二维码登录
手机登录
邮箱登录
+86
+1
+852
+886
+81
+65
+61
+44
获取验证码
登录 / 注册
关闭
二维码登录
手机登录
邮箱登录
获取验证码
登录 / 注册
热心肠智库
专家文章 | 王欣
2022
CA
Isomaltooligosaccharides Sustain the Growth of Prevotella Both In Vitro and in Animal Models
Microbiol Spectr, 10.1128/spectrum.02621-21
点击查看热心肠日报解读
CA
Isomaltooligosaccharides Sustain the Growth of Prevotella Both In Vitro and in Animal Models
Microbiol Spectr, 10.1128/spectrum.02621-21
点击查看热心肠日报解读
CA
Isomaltooligosaccharides Sustain the Growth of Prevotella Both In Vitro and in Animal Models
Microbiol Spectr, 10.1128/spectrum.02621-21
点击查看热心肠日报解读
CA
Isomaltooligosaccharides Sustain the Growth of Prevotella Both In Vitro and in Animal Models
Microbiol Spectr, 10.1128/spectrum.02621-21
点击查看热心肠日报解读
CA
Isomaltooligosaccharides Sustain the Growth of Prevotella Both In Vitro and in Animal Models
Microbiol Spectr, 10.1128/spectrum.02621-21
点击查看热心肠日报解读
2021
CA
Effects of Xylo-Oligosaccharide on the Gut Microbiota of Patients With Ulcerative Colitis in Clinical Remission
Front Nutr, 10.3389/fnut.2021.778542
CA
Carrageenan oligosaccharides and associated carrageenan-degrading bacteria induce intestinal inflammation in germ-free mice
JGG, 10.1016/j.jgg.2021.08.001
点击查看热心肠日报解读
2020
CA
Effect of chitooligosaccharides on human gut microbiota and antiglycation
CARBOHYD POLYM, 10.1016/j.carbpol.2020.116413
点击查看热心肠日报解读
2019
CA
Distribution and Strain Diversity of Immunoregulating Segmented Filamentous Bacteria in Human Intestinal Lavage Samples
Microb Ecol, 10.1007/s00248-019-01441-4
2018
CA
Presence of Segmented Filamentous Bacteria in Human Children and Its Potential Role in the Modulation of Human Gut Immunity
FMICB, 10.3389/fmicb.2018.01403
CA
To Construct an Engineered ( S)-Equol Resistant E. coli for in Vitro ( S)-Equol Production
FMICB, 10.3389/fmicb.2018.01182
CA
To Construct an Engineered ( S)-Equol Resistant E. coli for in Vitro ( S)-Equol Production
FMICB, 10.3389/fmicb.2018.01182
CA
To Construct an Engineered ( S)-Equol Resistant E. coli for in Vitro ( S)-Equol Production
FMICB, 10.3389/fmicb.2018.01182
CA
To Construct an Engineered ( S)-Equol Resistant E. coli for in Vitro ( S)-Equol Production
FMICB, 10.3389/fmicb.2018.01182
CA
To Construct an Engineered ( S)-Equol Resistant E. coli for in Vitro ( S)-Equol Production
FMICB, 10.3389/fmicb.2018.01182
CA
To Construct an Engineered ( S)-Equol Resistant E. coli for in Vitro ( S)-Equol Production
FMICB, 10.3389/fmicb.2018.01182
CA
To Construct an Engineered ( S)-Equol Resistant E. coli for in Vitro ( S)-Equol Production
FMICB, 10.3389/fmicb.2018.01182
CA
To Construct an Engineered ( S)-Equol Resistant E. coli for in Vitro ( S)-Equol Production
FMICB, 10.3389/fmicb.2018.01182
CA
To Construct an Engineered ( S)-Equol Resistant E. coli for in Vitro ( S)-Equol Production
FMICB, 10.3389/fmicb.2018.01182
CA
To Construct an Engineered ()-Equol Resistant for ()-Equol Production
FMICB, 10.3389/fmicb.2018.01182